SIC
RXRX icon

SJS Investment Consulting’s Recursion Pharmaceuticals RXRX Stock Holding History

SJS Investment Consulting’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$173 Buy
+47
New +$156 ﹤0.01% 2509
2025
Q2 		– Sell
-100
Closed -$529 – 1638
2025
Q1 		$529 Hold
100
– – ﹤0.01% 1228
2024
Q4 		$676 Hold
100
– – ﹤0.01% 1141
2024
Q3 		$659 Hold
100
– – ﹤0.01% 1229
2024
Q2 		$750 Hold
100
– – ﹤0.01% 1140
2024
Q1 		$997 Hold
100
– – ﹤0.01% 1041
2023
Q4 		$986 Buy
+100
New +$713 ﹤0.01% 963

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SJS Investment Consulting's RXRX Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 47 shares worth $173. The stake represents ﹤0.01% of the portfolio and ranks #2509 among its holdings. This is a return to the name: SJS Investment Consulting previously reported a position in RXRX as recently as Q1 2025.

SJS Investment Consulting first reported a position in RXRX in Q4 2023 and has held it in 7 quarters since. The position peaked at $997 in Q1 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • SJS Investment Consulting held 47 shares of Recursion Pharmaceuticals worth $173 as of Q2 2026.
  • Recursion Pharmaceuticals was a new SJS Investment Consulting position in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2509 holding.
  • SJS Investment Consulting first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 7 quarters since.
  • SJS Investment Consulting's Recursion Pharmaceuticals position peaked at $997 in Q1 2024.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.